Drug Trial Radar · NCT04703192
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)
Last checked: Nov 19, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
155
Actual
Start
Jun 3, 2021
Primary completion
May 10, 2023
Study completion Jun 19, 2029
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Jan 11, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T-cell leukemia/lymphoma.
Conditions
- Relapsed/Refractory Peripheral T-Cell Lymphoma
- Adult T Cell Leukemia/Lymphoma
Interventions
Valemetostat TosylateDrug
Oral administration of valemetostat tosylate at a dose of 200 mg once daily starting at Cycle 1, Day 1 (continuous for 28-day cycles), until disease progression or unacceptable toxicity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Objective Response As Assessed by Blinded Independent Central Review After Administration of Valemetostat Tosylate Monotherapy (Cohort 1)Time frame: From baseline until disease progression or death (whichever occurs first), up to approximately 23 months
- Number of Participants With Treatment-emergent Adverse Events After Administration of Valemetostat Tosylate Monotherapy (Cohort 2)Time frame: From the time the informed consent form is signed up to 30 days after last dose, up to 23 months
Locations
60 sites in 12 countries. Site status is shown where the registry gives one.
City Of Hope National Medical Center
Duarte, California
Stanford University Medical Center - Cancer Clinical Trials Office - ONCOLOGY
Palo Alto, California
University of California San Francisco
San Francisco, California
University Of Colorado Cancer Center
Aurora, Colorado
Emory University Hospital - Winship Cancer Institute
Atlanta, Georgia
Northwestern University - Feinberg School of Medicine
Chicago, Illinois
Dana Farber Cancer Institute
Boston, Massachusetts
Mayo Clinic - Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Hackensack University Medical Center - John Theurer Cancer Center
Hackensack, New Jersey
Memorial Sloan-Kettering Cancer Center at Memorial Hospital
New York, New York
Weill Cornell Medicine
New York, New York
Duke Cancer Center
Durham, North Carolina
University of Pennsylvania Perelman Center for Advanced Medicine
Philadelphia, Pennsylvania
Epworth Healthcare
Richmond, Australia
Ottawa Hospital Research Institute
Ottawa, Canada
University Health Network Princess Margaret Hospital
Toronto, Canada
BC Cancer - Vancouver Centre
Vancouver, British Columbia, Canada
CHU de Dijon
Dijon, France
CHRU de Lille - Hôpital Claude Huriez - Maladies du Sang
Lille, France
Centre Lyon Berard - Medical Oncology
Lyon, France
APHP - Hopital Saint Louis
Paris, France
Hôpital Necker
Paris, France
Centre Hospitalier Lyon Sud - Hématologie
Pierre-Bénite, France
Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-Oncopole)
Toulouse, France
Universitätsklinikum Halle (Saale) - Klinik und Poliklinik für Innere Medizin IV
Halle, Germany
ASST Papa Giovanni XXIII - Medicina Trasfusionale ed Ematologia - Bergamo
Bergamo, Italy
A.O.di Bologna Policl.S.Orsola
Bologna, Italy
PO San Gerardo, ASST Monza
Monza, Italy
Fondazione Pascale, IRCCS, Istituto Nazionale dei Tumori
Naples, Italy
Ospedale S.Maria della Misericordia, AO di Perugia, Università degli Studi di Perugia
Perugia, Italy
Kyushu University Hospital
Fukuoka, Japan
Kagoshima University Hospital
Kagoshima, Japan
University Hospital - Kyoto Prefectural University of Medicine
Kyoto, Japan
Nagasaki University Hospital
Nagasaki, Japan
Okayama University Hospital
Okayama, Japan
National Hospital Organization Nagoya Medical Center - Hematology
Nagoya, Aichi-ken, Japan
Nagoya City University Hospital
Nagoya, Aichi-ken, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Hokkaido University Hospital - Medical Oncology Center
Sapporo, Hokkaido, Japan
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.